ZURA Company Profile and Key Details

Zura Bio Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.35. This means the shares are trading above this model’s fair value.

Zura Bio Limited (NASDAQ:ZURA) closed at $5.99 USD, losing -$0.45 (-6.99%) from the previous close of $6.44. The stock is currently mid-range between its 52-week high and low $0.97 and $7.44. With a market capitalization of about $389.48 million, Zura Bio Limited is classified as a small-cap and shows lower-than-market volatility (beta ~0.18). Key stats such as the average daily volume over the past year has been around 683.83 thousand shares, in line with its 52-week average. Headquartered in San Diego, CA, Zura Bio Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sandeep C. Kulkarni, the company employs approximately 30 people and listed since March 21, 2023. Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.

Wall Street analysts project EPS growth of -3.66% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 6 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $19.00 to $2.00. The high target offers 217.2% upside. The low target suggests -66.61% downside. The mean target is $11.64. This offers 94.32% upside. Zura Bio Limited earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 11.52%. The prior quarter beat by -10.53%. Over the last six quarters, Apple has recorded several small beats. These include 30.77% in August 13, 2024.

Zura Bio Limited trades at a P/E ratio of -9.16, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.29 trading at moderately above to book value. The P/FCF stands at -7.36, also below market averages.

Zura Bio Limited (NASDAQ:ZURA) shares are flat -4.39% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Zura Bio Limited trading at a premium to the broader market with a P/E of -9.16. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $11.73, suggesting 95.83% upside. Our AI forecast model points to short-term strength (11.19% over two weeks), a medium-term fall (-37.06% over three months), and a longer-term gain (825.88% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Zura Bio Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.19%, with price expected at $6.66 by March 31, 2026, within a range of $6.35 to $6.95 3-Month Outlook: Projected fall of -37.06%, reaching $3.77 by June 15, 2026, with a range of $3.53 to $3.99. 1-Year Outlook: Projected gain of 825.88%, with price at $55.46 by March 17, 2027, within a range of $52.31 to $68.48.